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Introduction
Although bone strength and fracture risk are generally
assessed by measuring bone mineral density (BMD), the
mechanical properties of bone are in fact determined not
only by bone mass, but also by the architecture/geometry of
the bone and by the intrinsic material properties of the tissue.
Fracture risk increases with age, partly as a function of
changes in BMD. However, the risk of fracture in a 75-year-
old woman is 4-7 times that in a 45-year-old woman with an
identical bone mass1. This demonstrates that there is a com-
ponent to bone fragility that is independent of bone mass, and
determined by bone quality. This has been emphasized
recently by the observation that anti-resorptive treatments for
osteoporosis all have about the same fracture efficacy, though
there is a seven-fold difference in their effect on BMD.
Bone quality is defined by at least four factors: (1) the rate
of bone turnover; (2) properties of the collagen/mineral
matrix; (3) microdamage accumulation; (4) architecture/geom-
etry of cancellous and cortical bone.
Bone turnover
Vertebral fracture risk is determined by both BMD and
turnover rate2. Rapid turnover accelerates osteoclastic
resorption on trabecular surfaces that can reduce their
resistance to buckling and make failure more likely3.
Resorption lacunae on trabecular surfaces are responsible
for larger decreases in bone stiffness than in trabecular thin-
ning4. Additionally, the resorption bays create stress concen-
trations that may promote the initiation of microcracks.
More rapid turnover also increases the probability for perfo-
ration and elimination of trabecular struts. A 50% reduction
in turnover can result in a 4-fold reduction in trabecular per-
foration5. However, agents such as teriparatide that increase
turnover also may lower fracture risk by increasing net bone
formation on trabecular surfaces.
Matrix mineralization
The amount of energy that can be absorbed before frac-
ture is reduced by either hypo- or hypermineralization of the
bone tissue6,7. Suppression of remodeling increases tissue
mineralization by lengthening the period of time over which
secondary mineralization can occur8-12. This may increase the
tendency for microcracks to initiate. As importantly, remod-
eling suppression increases tissue homogeneity, possibly
making crack growth easier as well. However, the magnitude
of the effect is probably determined by the amount of sup-
pression. On the other hand, teriparatide stimulates
increased bone turnover and increases the heterogeneity of
the tissue matrix.
Collagen
The collagen matrix has a profound effect on bone’s
mechanical properties13. The risk of vertebral fracture is sig-
nificantly increased in subjects with the Sp1 polymorphism
of the COL1A1 gene14. Changes in collagen with aging are
known to affect the amount of energy required to cause frac-
ture15. This may have to do either with the amount of colla-
gen in the matrix, or with the extent or nature of its cross-
linking. Anti-resorptive treatments probably increase the
amount of cross-linking, but whether this is a positive or a
negative change is unclear at this time.
Microdamage
Microdamage accumulation reduces bone’s strength, stiff-
ness and toughness16. Bone from older women is more sus-
ceptible to the initiation of microcracks17 and must be inher-
ently more fragile than bone from younger women. This may
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be why there is a significant accumulation of microdamage at
several anatomical sites with age18-21. Suppression of remod-
eling pharmaceutically also increases damage accumula-
tion22,23; the extent of this increase is probably dependent on
the magnitude of the suppression24.
Architecture/Geometry
Cancellous bone that is more plate-like, with thicker and
more trabeculae, enhances strength. Trabecular architecture
that is more isotropic, having similar mechanical properties
in all directions, may lower fracture risk further. This could
provide a rationale for the clinical observation that fracture
risk decreases by 50-60% in the first year of bisphosphonate
therapy with only a 5% increase in bone mineral density.
Teriparatide increases trabecular number and connectivity
via longitudinal tunneling, converting thickened trabeculae
to multiple struts of normal thickness25. Although it increas-
es cortical porosity, the porosity is located close to the mar-
row cavity where its mechanical effect is small26,27.
Simultaneously, teriparatide allows periosteal apposition,
which maintains or improves cortical bone strength28.
Conclusion
It is quite clear that the assessment of bone quality as
defined here, in addition to BMD measurement, is impor-
tant to determine fracture risk, but techniques to measure
these properties are nascent. Development of new non-inva-
sive techniques will be necessary to provide better pre-frac-
ture evaluations of tissue quality. These will need to be made
accessible and convenient for the health practitioner.
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